Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer
December 7th 2023Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Read More
Neoadjuvant Chemotherapy Does Not Give Survival Benefit Over Chemoradiation in Cervical Cancer
December 3rd 2023Neoadjuvant chemotherapy preceding surgery did not result in a significant difference in 5-year overall survival rates compared with concomitant chemoradiotherapy in patients with stage IB2 to IIB cervical carcinoma, according to findings from the phase 3 EORTC-55994 trial.
Read More
Adding Pemetrexed to Cisplatin Does Not Result in Survival Benefit Over Vinorelbine in NSCLC
December 2nd 2023Adjuvant treatment with the chemotherapy doublet of pemetrexed and cisplatin did not lead to a significant improvement in overall survival compared with vinorelbine plus cisplatin in patients with stage II to IIIA nonsquamous non–small cell lung cancer.
Read More
Cretostimogene Grenadenorepvec Confers High CR Rate in NMIBC
December 1st 2023Preliminary findings from the phase 3 BOND-003 trial showed that treatment with cretostimogene grenadenorepvec led to sustained and durable complete responses and a tolerable safety profile in patients with high-risk non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
Read More
EG12014 Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers
November 28th 2023EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union for the treatment of patients with HER2-positive breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the EU.
Read More
PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors
November 27th 2023Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.
Read More
Lenalidomide Plus Rituximab Elicits Prolonged Responses in Mantle Cell Lymphoma
November 20th 2023Initial induction therapy with the immunomodulatory agent lenalidomide plus the anti-CD20 monoclonal antibody rituximab led to prolonged, durable responses with a manageable safety profile in patients with previously untreated mantle cell lymphoma.
Read More
Allogeneic HCT Provides OS Benefit Independent of TP53 Allelic Status in MDS
November 18th 2023Patients with myelodysplastic syndrome harboring a TP53 mutation experienced a survival benefit with allogeneic hematopoietic cell transplantation compared with non-HCT treatment regardless of TP53 allelic status.
Read More
Zanubrutinib Plus Obinutuzumab Gets EU Approval for R/R Follicular Lymphoma
November 17th 2023The European Commission has granted marketing authorization to the combination of zanubrutinib and obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of systemic therapy.
Read More
NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines
November 13th 2023TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recurrent, unresectable, or metastatic salivary gland tumors who were not eligible for surgery or radiation therapy.
Read More
Recent Developments in Ovarian and Endometrial Cancers Stir Excitement Among Clinicians
November 7th 2023Despite advanced ovarian and endometrial cancer still being accompanied by a poor prognosis and remaining largely difficult-to-treat diseases, optimism among clinicians has steadily ramped up in recent years with the development of multiple new promising agents and treatment regimens.
Read More
ASCO Recommends Trilaciclib in Extensive-Stage Small Cell Lung Cancer in Guideline Update
November 6th 2023In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.
Read More
Successful Bladder Cancer Programs Rely on Old Pillars, New Innovations
November 2nd 2023Building a successful bladder cancer program requires clinicians to employ a multifaceted approach that prioritizes good surgical practices, embraces immunotherapies with an understanding of the adverse effects that can accompany them, and being up to date in terms of options for patients.
Read More
AON Goes Public, Aims to Leverage Increased Resources Into Improved Patient Care
November 1st 2023On September 20, 2023, with the goal of improving care, the American Oncology Network announced the completion of its business combination with Digital Transformation Opportunities Corp to become a publicly traded entity.
Read More
Maintenance Ibrutinib Leads to High PFS, OS Rates in MCL After Frontline Induction Therapy
October 27th 2023Maintenance ibrutinib following frontline induction therapy was proven to be effective in patients with treatment-naïve mantle cell lymphoma , according to findings from a phase 2 trial published in Blood Advances.
Read More
Early Trials of PRMT5 Inhibitors Leave Much to Be Desired, But Optimism Remains
October 27th 2023Despite the discovery of protein arginine methyltransferase 5 more than 20 years ago, interest in the potential oncogene as a treatment target for patients with hematologic and solid malignancies has increased in recent years with the advancement of multiple novel agents through preclinical and early-phase studies.
Read More